FindMyRecallSubscribe
Class II: temporary or reversible health riskOngoing

Ajanta Pharma Duloxetine Delayed-Release Capsules Recall

Duloxetine Delayed-Release Capsules, 60 mg, Rx Only, 30 capsules, Marketed by: Ajanta P…

Ajanta Pharma Ltd.

Risk level
Class II
Reported by FDA
May 13, 2026
Recall ID
D-0515-2026
Check your lot numberHow we source this data

Summary

Ajanta Pharma recalled Duloxetine Delayed-Release Capsules starting Apr 29, 2026. The FDA classified it as Class II (temporary or reversible health risk) and published enforcement report D-0515-2026 on May 13, 2026. Reason: CGMP Deviations: Presence of N-nitroso-Duloxetine impurity above FDA recommended limit of 0.83 ppm, identified at the 12-month and 18-month long-term stability intervals. Status: Ongoing.

Why it was recalled

CGMP Deviations: Presence of N-nitroso-Duloxetine impurity above FDA recommended limit of 0.83 ppm, identified at the 12-month and 18-month long-term stability intervals.

Product description

Duloxetine Delayed-Release Capsules, 60 mg, Rx Only, 30 capsules, Marketed by: Ajanta Pharma USA Inc., Bridgewater, NJ 08807, Made in India, NDC 27241-099-03

Lot numbers, UPCs & expiration codes

Lot#: PA07434, Exp. May 2026.

Where it was sold

Nationwide within U.S

What to do if you have this product

  • Compare the lot number and expiration date on your package with the codes above.
  • Don't stop taking a prescription medicine on your own. Call your pharmacist or doctor; they can confirm whether your supply is affected and arrange a replacement.
  • If you have symptoms you think are related, contact your doctor. In an emergency call 911.
  • Report side effects to FDA MedWatch at 1-800-FDA-1088.

Recall details

Recall number
D-0515-2026
Classification
Class II
Status
Ongoing
Recall initiated
Apr 29, 2026
FDA report date
May 13, 2026
Quantity
77,376 packs.
Recall type
Voluntary: Firm initiated
Recalling firm
Ajanta Pharma Ltd.

Original FDA data

Every field from FDA enforcement report D-0515-2026, exactly as published.

Show all FDA fields
City
Aurangabad
Status
Ongoing
Country
India
Event ID
98785
Address
B-4/5/6 MIDC Industrial Area
Address (line 2)
Paithan
Code information
Lot#: PA07434, Exp. May 2026.
Report date
May 13, 2026
Product type
Drugs
Recall number
D-0515-2026
Classification
Class II
Recalling firm
Ajanta Pharma Ltd.
Product quantity
77,376 packs.
Reason for recall
CGMP Deviations: Presence of N-nitroso-Duloxetine impurity above FDA recommended limit of 0.83 ppm, identified at the 12-month and 18-month long-term stability intervals.
Voluntary / mandated
Voluntary: Firm initiated
Product description
Duloxetine Delayed-Release Capsules, 60 mg, Rx Only, 30 capsules, Marketed by: Ajanta Pharma USA Inc., Bridgewater, NJ 08807, Made in India, NDC 27241-099-03
Distribution pattern
Nationwide within U.S
Recall initiation date
Apr 29, 2026
Initial firm notification
Letter
Center classification date
May 4, 2026

How we source this data

Source: U.S. Food and Drug Administration enforcement report D-0515-2026, published May 13, 2026. View the source record (openFDA) · FDA enforcement reports

Last checked against FDA data: . Content last changed: .

FindMyRecall is an independent service and is not affiliated with or endorsed by the FDA. This page simplifies the official record; the FDA or manufacturer notice is authoritative, so follow its instructions. Medication information here is not individualized medical advice.

How we source and update recall data · Report incorrect information

Other recent drug recalls